Summary
Global Markets Direct’s, ‘Immune Pharmaceuticals Inc. - Product Pipeline Review, 2016’, provides an overview of the Immune Pharmaceuticals Inc.’s pharmaceutical research and development focus.
The report provides comprehensive information on the therapeutics under development by Immune Pharmaceuticals Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the pipeline therapeutic landscape of Immune Pharmaceuticals Inc.
- The report provides overview of Immune Pharmaceuticals Inc. including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Immune Pharmaceuticals Inc.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Immune Pharmaceuticals Inc.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects
Reasons to buy
- Evaluate Immune Pharmaceuticals Inc.’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Immune Pharmaceuticals Inc.
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Immune Pharmaceuticals Inc.’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
'
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Immune Pharmaceuticals Inc. Snapshot 6
Immune Pharmaceuticals Inc. Overview 6
Key Information 6
Key Facts 6
Immune Pharmaceuticals Inc. - Research and Development Overview 7
Key Therapeutic Areas 7
Immune Pharmaceuticals Inc. - Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products - Monotherapy 11
Pipeline Products - Combination Treatment Modalities 12
Pipeline Products - Partnered Products 13
Partnered Products/Combination Treatment Modalities 14
Immune Pharmaceuticals Inc. - Pipeline Products Glance 15
Immune Pharmaceuticals Inc. - Late Stage Pipeline Products 15
Phase III Products/Combination Treatment Modalities 15
Immune Pharmaceuticals Inc. - Clinical Stage Pipeline Products 16
Phase II Products/Combination Treatment Modalities 16
Phase I Products/Combination Treatment Modalities 17
Immune Pharmaceuticals Inc. - Early Stage Pipeline Products 18
IND/CTA Filed Products/Combination Treatment Modalities 18
Preclinical Products/Combination Treatment Modalities 19
Immune Pharmaceuticals Inc. - Drug Profiles 20
histamine dihydrochloride 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
(amitriptyline + ketamine hydrochloride) 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
bertilimumab 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
crolibulin 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
lidocaine hydrochloride 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
F-573 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
cyclosporine 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Ferritizumab 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Monoclonal Antibodies to Target HLA-DR and CD5 for Leukemia 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Monoclonal Antibody Conjugate for Non-Small Cell Lung Cancer and Pancreatic Cancer 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Monoclonal Antibody Conjugate to Target EGFR for Non-Small Cell Lung Cancer 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Monoclonal Antibody Conjugate to Target HER2 for Metastatic Prostate Cancer 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Monoclonal Antibody Conjugate to Target HER3 for Solid Tumors 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
verubulin 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Immune Pharmaceuticals Inc. - Pipeline Analysis 42
Immune Pharmaceuticals Inc. - Pipeline Products by Target 42
Immune Pharmaceuticals Inc. - Pipeline Products by Route of Administration 44
Immune Pharmaceuticals Inc. - Pipeline Products by Molecule Type 45
Immune Pharmaceuticals Inc. - Pipeline Products by Mechanism of Action 46
Immune Pharmaceuticals Inc. - Recent Pipeline Updates 48
Immune Pharmaceuticals Inc. - Dormant Projects 57
Immune Pharmaceuticals Inc. - Discontinued Pipeline Products 58
Discontinued Pipeline Product Profiles 58
histamine dihydrochloride 58
verubulin 58
Immune Pharmaceuticals Inc. - Locations And Subsidiaries 59
Head Office 59
Other Locations & Subsidiaries 59
Appendix 60
Methodology 60
Coverage 60
Secondary Research 60
Primary Research 60
Expert Panel Validation 60
Contact Us 60
Disclaimer 61
List of Tables
Immune Pharmaceuticals Inc., Key Information 6
Immune Pharmaceuticals Inc., Key Facts 6
Immune Pharmaceuticals Inc. - Pipeline by Indication, 2016 8
Immune Pharmaceuticals Inc. - Pipeline by Stage of Development, 2016 10
Immune Pharmaceuticals Inc. - Monotherapy Products in Pipeline, 2016 11
Immune Pharmaceuticals Inc. - Combination Treatment Modalities in Pipeline, 2016 12
Immune Pharmaceuticals Inc. - Partnered Products in Pipeline, 2016 13
Immune Pharmaceuticals Inc. - Partnered Products/ Combination Treatment Modalities, 2016 14
Immune Pharmaceuticals Inc. - Phase III, 2016 15
Immune Pharmaceuticals Inc. - Phase II, 2016 16
Immune Pharmaceuticals Inc. - Phase I, 2016 17
Immune Pharmaceuticals Inc. - IND/CTA Filed, 2016 18
Immune Pharmaceuticals Inc. - Preclinical, 2016 19
Immune Pharmaceuticals Inc. - Pipeline by Target, 2016 42
Immune Pharmaceuticals Inc. - Pipeline by Route of Administration, 2016 44
Immune Pharmaceuticals Inc. - Pipeline by Molecule Type, 2016 45
Immune Pharmaceuticals Inc. - Pipeline Products by Mechanism of Action, 2016 46
Immune Pharmaceuticals Inc. - Recent Pipeline Updates, 2016 48
Immune Pharmaceuticals Inc. - Dormant Developmental Projects,2016 57
Immune Pharmaceuticals Inc. - Discontinued Pipeline Products, 2016 58
Immune Pharmaceuticals Inc., Other Locations 59
Immune Pharmaceuticals Inc., Subsidiaries 59
List of Figures
Immune Pharmaceuticals Inc. - Pipeline by Top 10 Indication, 2016 8
Immune Pharmaceuticals Inc. - Pipeline by Stage of Development, 2016 10
Immune Pharmaceuticals Inc. - Monotherapy Products in Pipeline, 2016 11
Immune Pharmaceuticals Inc. - Partnered Products in Pipeline, 2016 13
Immune Pharmaceuticals Inc. - Pipeline by Top 10 Target, 2016 42
Immune Pharmaceuticals Inc. - Pipeline by Route of Administration, 2016 44
Immune Pharmaceuticals Inc. - Pipeline by Molecule Type, 2016 45
Immune Pharmaceuticals Inc. - Pipeline Products by Top 10 Mechanism of Action, 2016 46
